Pioneering
THE FUTURE OF CANCER TREATMENT
Cancer does not just affect the people with the disease — it also impacts families, communities, and even our beloved pets. At Metanoi Therapeutics, we harness cutting-edge science to deliver life-changing treatments, offering hope to patients and families worldwide.
Malignant tumors are composed of diverse cancer cells that can adapt, morph, and evade traditional therapies over time. These cells, however, share a common vulnerability: inefficient energy production, making them heavily reliant on glucose and glutamine. Among other things, our drug exploits this weakness by downregulating HIF1-alpha, which is crucial for energy production in low-oxygen environments. This approach is particularly important for cancer cells, which often experience low oxygen levels and must find alternative ways to produce energy to continue growing. Contact us for our detailed deck or for more information on the science behind our company.
VET001 (Animals): Targeting an Investigational New Animal Drug (INAD) for dogs.
MET001 (Humans): Targeting Investigational New Drug (IND) submission for Phase I human trials.
At Metanoi Therapeutics, we aren’t just creating treatments—we’re giving patients and their families HOPE.
In 2025, according to the American Cancer Society, the United States is expected to see over 2 million new cancer cases for the first time, which is almost 5,600 new cases each day.
According to the World Health Organization, the number of cancer cases is projected to rise by 55% from 2020 to 2040.
In the US, 6 million new cases of dog cancer are diagnosed each year, which is the leading cause of death in adult dogs.
With groundbreaking solutions for humans and pets, we are poised to impact two high-potential markets:
We are driving groundbreaking research and development across critical milestones, including the following:
Launch clinical trials
for VET001 and take to market in 18-24 months
Using data from the animal trials, submit IND for
human trials
IPO and initiate Phase 1 human trials
Your investment can help bring life-saving solutions to millions, reshaping the future of cancer care for humans and animals. Click below to contact us for more information on the science behind our company.
Cancer affects us all. Whether you are a patient, caregiver, or investor, you have the power to make a difference. Join us in shaping a future where cancer care is safe, effective, and accessible to all. Contact us for our detailed deck or for more information on the science behind our company.
This website contains forward-looking statements, which include estimates, projections, and statements about future plans, strategies, and anticipated results. These statements are based on current expectations and assumptions but are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Actual outcomes may differ materially due to factors such as regulatory approval timelines, clinical trial results, competitive developments, and market acceptance. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including but not limited to:Clinical development risks, including delays in trials or regulatory approvals.Market risks, including changes in demand or competition.Financial risks, including funding requirements and projections.Nothing on this site constitutes an offer to sell or a solicitation to purchase securities. Investors should not place undue reliance on forward-looking statements, and any decision to invest should be based on thorough due diligence and consultation with financial and legal advisors. For detailed information, please review the full disclosure provided by Metanoi Therapeutics.
